Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE February 23, 2016 LeafBio Announces Conclusion of ZMapp™ Clinical Trial Therapy to Treat Ebola Shows Promise February 23, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today results from the Prevail II clinical trial
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE January 07, 2016 Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes Leaf Bio’s MB66 Developed as Multipurpose Prevention Technology January 7, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 15, 2015 ZMapp™ is Granted Orphan Medicinal Product Designation by the EMA Status May Enable Faster Approval of ZMapp™ October 15, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE September 17, 2015 ZMapp™ is Granted Fast Track Status by the FDA Status May Enable Faster Approval of ZMapp™ September 17, 2015 – SAN DIEGO – LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced today that the
Public Health Agency of Canada Ottawa, ON FOR IMMEDIATE RELEASE June 10, 2015 Government of Canada strengthens Ebola preparedness for Canadians Contract signed to manufacture ZMappTM to help protect Canadians The Honourable Rona Ambrose, Minister of Health, and Canada’s Chief Public Health Officer, Dr. Gregory Taylor, today announced a $4.5
LeafBio Announces Acceptance of Investigational New Drug Application for Ebola Therapy ZMapp™ Clears Way for Human Trials of ZMapp in Liberia February 27, 2015 – SAN DIEGO – LeafBio, the commercial arm of Mapp Biopharmaceutical, announced that it has received approval of its application for an Investigational New Drug (IND)
NEWS RELEASE Web Site Release July 15, 2014 Toronto, ON – today Defyrus announced an exclusive, worldwide license to their Ebola therapeutic monoclonal antibody (mAb) patent portfolio to Leaf Biopharmaceutical Inc. of San Diego, CA. This license expands the commercial relationship between LeafBio and Defyrus who have been actively collaborating
Contact: Caree Vander Linden (301) 619-2285 Fort Detrick, Maryland Caree.VanderLinden@us.army.mil EMBARGOED FOR RELEASE: August 21, 2013 – 2:00 PM Eastern Time Experimental Ebola Treatment Protects Some Primates Even After Disease Symptoms Appear Scientists have successfully treated the deadly Ebola virus in infected animals following onset of disease symptoms, according to
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies. In this week’s online edition of the Proceedings of the National Academy of Sciences (PNAS), the research team describes a proof-of-concept for using a “cocktail”